Bayer Stock News

LEVERKUSEN, Germany, Aug. 15, 2025 (GLOBE NEWSWIRE) -- LumenHaus, Germany's forefront innovator in smart home energy solutions, has officially signed as an Official Premium Partner of Bayer 04 Leverkusen for the 2025/26 season, marking the start of a collaboration that blends tradition, innovation, and sustainability. This partnership brings together LumenHaus' smart energy solutions with the d...

BERLIN & SAN DIEGO--(BUSINESS WIRE)--Bayer and Kumquat Biosciences Inc., a clinical-stage biotech company founded by pioneers of the KRAS pathway, today announced that they have entered into an exclusive global license and collaboration to develop and commercialize Kumquat's KRAS G12D inhibitor. Under the agreement, Kumquat is responsible for the initiation and completion of the Phase Ia study,...

German pharmaceutical group Bayer announced on Tuesday a deal worth up to $1.3 billion with Kumquat Biosciences to develop the U.S.-based oncology specialist's potential new cancer drug.

Under the global exclusive license deal, Kumquat will be responsible for the Phase 1a study of its inhibitor and Bayer will take the drug to market.

Die Privatbank Berenberg hat die Einstufung für Bayer DE000BAY0017 auf "Hold" mit einem Kursziel von 26 Euro belassen.

Bayer A.G. (OTCPK:BAYZF) Q2 2025 Earnings Conference Call August 6, 2025 8:00 AM ET Company Participants Jost Reinhard - Senior VP & Head of Investor Relations Rodrigo Santos - Member of Management Board & President of the Crop Science Division Stefan Oelrich - Head of the Pharmaceuticals Division & Member of the Board of Management William N. Anderson - Chairman of the Management Board & CEO W...

Bayer said on Wednesday it had cut about 12,000 full-time positions since the start of a restructuring programme to speed up decision-making and reduce managerial and administrative positions.

Die Aktien von Bayer DE000BAY0017 sind am Mittwoch nach endgültigen Quartalszahlen deutlich unter Druck geraten.